Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Stopped early · Phase 3

Conditions studied: Relapsing Multiple Sclerosis

In brief

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

Key facts

Study ID: NCT04338022
Run by: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
People needed: 1124
Starts: 2020-06-12
Expected to finish: 2024-03-08
Last updated by the study team: 2025-06-12

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score <= 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
Participants have given written informed consent prior to any study-related procedure
Other protocol defined inclusion criteria could apply.

You may not qualify if…

Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b).
Participants with secondary progressive MS without evidence of relapse
Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at screening and Baseline (Day 1)
Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV) , intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
Other protocol defined exclusion criteria could apply.

Where it is running

Research Site 614 — Phoenix, Arizona, United States
Research Site 677 — Phoenix, Arizona, United States
Research Site 642 — Long Beach, California, United States
Research Site 644 — Pasadena, California, United States
Research Site 672 — San Diego, California, United States
Research Site 634 — Stamford, Connecticut, United States
Research Site 656 — Washington D.C., District of Columbia, United States
Research Site 616 — Boca Raton, Florida, United States
Research Site 625 — Maitland, Florida, United States
Research Site 617 — Miami, Florida, United States
Research Site 643 — Ormond Beach, Florida, United States
Research site 645 — St. Petersburg, Florida, United States
Research Site 652 — Tallahassee, Florida, United States
Research Site 621 — Elk Grove Village, Illinois, United States
Research Site 649 — Northbrook, Illinois, United States
Research Site 675 — Peoria, Illinois, United States
Research Site 628 — Rolling Meadows, Illinois, United States
Research Site 624 — Indianapolis, Indiana, United States
Research Site 632 — Kansas City, Kansas, United States
Research Site 653 — New Orleans, Louisiana, United States
Research Site 623 — Baltimore, Maryland, United States
Research Site 633 — Boston, Massachusetts, United States
Research Site 639 — Foxborough, Massachusetts, United States
Research Site 635 — Lawrence, Massachusetts, United States
Research Site 629 — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.